Evidence-based initiation of dopaminergic therapy in Parkinson's disease
- 202 Downloads
The mainstay of Parkinson's disease (PD) therapy is levodopa. The crucial question is when should levodopa be initiated? Levodopa provides the most potent motor benefit for PD, but longer term use is marked by the development of motor complications such as fluctuations in response and involuntary motor movements. Dopamine agonists reduce the risk of development of motor complications in the 5-year term. However, side effects may change the risk-benefit of dopamine agonist first strategies. In the following, the evidence for levodopa and dopamine agonists as initial monotherapy for PD is examined.
KeywordsParkinson disease Initiation of therapy Evidence-based practice Dopamine agonists Levodopa
- 7.Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C (2007) New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonis treatment and age at motor symptoms onset. J Psychopharmacol 21(5):501–506CrossRefPubMedGoogle Scholar
- 23.Parkinson study group (2000) Beta CIT-SPECT assessment of progression of Parkinson’s disease in subjects participating in the CALM-PD study. Neurology 54:A90Google Scholar
- 26.Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P, The Chinese Parkinson study group (2009) Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771CrossRefPubMedGoogle Scholar
- 33.Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy MA, Whetteckey J, Wunderlich GR, Lang AE (2008) Mov Disord 23(S1)PosterGoogle Scholar